The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders

Drug News and Perspectives

Volumn 20, Issue 6, 2007, Pages 365-370

  Gong, Bing ^a   Leznik, Elena ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UBIQUITIN C TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DNA POLYMORPHISM; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUNTINGTON CHOREA; MUTATIONAL ANALYSIS; NONHUMAN; PARKINSON DISEASE; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; STEADY STATE;

ALZHEIMER DISEASE; DRUG DELIVERY SYSTEMS; HUMANS; HUNTINGTON DISEASE; MUTATION; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN THIOLESTERASE;

EID: 36849001303     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2007.20.6.1138160     Document Type: Review

References (68)

1. Wilkinson, K.D., Tashayev, V.L., O'Connor, L.B. et al. Metabolism of the polyubiquitin degradation signal: Structure, mechanism, and role of isopeptidase T. Biochemistry 1995, 34: 14535-46.
2. Wilkinson, K.D. Ubiquitination and deubiquitination: Targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000, 11: 141-8.
3. Wilkinson, K.D. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 1997, 11: 1245-56.
4. Chung, C.H. and Baek, S.H. Deubiquitinating enzymes: their diversity and emerging roles. Biochem Biophys Res Commun 1999, 266: 633-40.
5. Papa, F.R., Amerik, A.Y. and Hochstrasser, M. Interaction of the Doa4 deubiquitinating enzyme with the yeast 26S proteasome. Mol Biol Cell 1999, 10: 741-56.
6. Wilkinson, K.D., Lee, K.M., Deshpande, S. et al. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989, 246: 670-3.
7. Day, I.N.M. and Thompson, R.J. Molecular cloning of cDNA coding for human PGP 9.5 protein: A novel cytoplasmic marker for neurones and neuroendocrine cells. FEBS Lett 1987, 210: 157-60.
8. Larsen, C.N., Price, J.S. and Wilkinson, K.D. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: Identification of two active site residues. Biochemistry 1996, 35: 6735-44.
9. Liu, Y., Fallon, L., Lashuel, H.A. et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111: 209-18.
10. Betarbet, R., Sherer, T.B. and Greenamyre, J.T. Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 2005, 191(Suppl. 1): S17-27.
11. Giasson, B.I. and Lee, V.M. Are ubiquitination pathways central to Parkinson's disease? Cell 2003, 114: 1-8.
12. Osaka, H., Wang, Y.L., Takada, K. et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 2003, 12: 1945-58.
13. Imai, Y., Soda, M. and Takahashi, R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 2000, 275: 35661-4.
14. Rubinsztein, D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443: 780-6.
15. Toda, T., Momose, Y., Murata, M. et al. Toward identification of susceptibility genes for sporadic Parkinson's disease. J Neurol 2003, 250 (Suppl 3): III40-3.
16. Satoh, J.I. and Kuroda, Y. Ubiquitin C-terminal hydrolase-L1 (PGP9.5) expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines, neurotrophic factors or heat stress. Neuropathol Appl Neurobiol 2001, 27: 95-104.
17. Wintermeyer, P., Kruger, R., Kuhn, W. et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport 2000, 11: 2079-82.
18. Leroy, E., Boyer, R., Auburger, G. et al. The ubiquitin pathway in Parkinson's disease. Nature 1998, 395: 451-2.
19. Naze, P., Vuillaume, I., Destee, A. et al. Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Neurosci Lett 2002, 328: 1-4.
20. Metzger, S., Bauer, P., Tomiuk, J. et al. The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. Neurogenetics 2006, 7: 27-30.
21. Anderson, S., Winefield, A., Delfabbro, P. et al. Psychological well-being and work attitudes across a range of employment status categories. Med Lav 2006, 97: 158-9.
22. Pasinetti, G.M. Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia. J Neurosci Res 2001, 65: 471-6.
23. Castegna, A., Aksenov, M., Thongboonkerd, V. et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 2002, 82: 1524-32.
24. Choi, J., Levey, A.I., Weintraub, S.T. et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 2004, 279: 13256-64.
25. Healy, D.G., Abou-Sleiman, P.M., Quinn, N. et al. UCHL-1 gene in multiple system atrophy: A haplotype tagging approach. Mov Disord 2005, 20: 1338-43.
26. Saigoh, K., Wang, Y.L., Suh, J.G. et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999, 23: 47-51.
27. DeLong, M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990, 13: 281-5.
28. Greenamyre, J.T. Glutamate-dopamine interactions in the basal ganglia: Relationship to Parkinson's disease. J Neural Transm Gen Sect 1993, 91: 255-69.
29. Klockgether, T. and Turski, L. Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 1989, 12: 285-6.
30. Braak, H. and Braak, E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995, 16: 271-8.
31. Spillantini, M.G., Schmidt, M.L., Lee, V.M. et al. Alpha-synuclein in Lewy bodies. Nature 1997, 388: 839-40.
32. Polymeropoulos, M.H., Lavedan, C., Leroy, E. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276: 2045-7.
33. Dawson, T.M. and Dawson, V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302: 819-22.
34. Lowe, J., McDermott, H., Landon, M. et al. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 1990, 161: 153-60.
35. Glickman, M.H. and Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002, 82: 373-428.
36. Maraganore, D.M., Farrer, M.J., Hardy, J.A. et al. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999, 53: 1858-60.
37. Zhang, J., Hattori, N., Leroy, E. et al. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat Disord 2000, 6: 195-7.
38. Mellick, G.D. and Silburn, P.A. The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease. Neurosci Lett 2000, 293: 127-30.
39. Levecque, C., Destee, A., Mouroux, V. et al. No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J Neural Transm 2001, 108: 979-84.
40. Harper, P.S. Huntington's Disease. W.B. Saunders: London, 1991.
41. Ross, C.A. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002, 35: 819-22.
42. Ross, C.A., Wood, J.D., Schilling, G. et al. Polyglutamine pathogenesis. Philos Trans R Soc Lond B Biol Sci 1999, 354: 1005-11.
43. Zoghbi, H.Y. and Orr, H.T. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000, 23: 217-47.
44. Lieberman, M.D. Intuition: A social cognitive neuroscience approach. Psychol Bull 2000, 126: 109-37.
45. Lin, X., Cummings, C.J. and Zoghbi, H.Y. Expanding our understanding of polyglutamine diseases through mouse models. Neuron 1999, 24: 499-502.
46. de Pril, R., Fischer, D.F., Maat-Schieman, M.L. et al. Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum Mol Genet 2004, 13: 1803-13.
47. Koos, T. and Tepper, J.M. Inhibitory control of neosiriatal projection neurons by GABAergic interneurons. Nat Neurosci 1999, 2: 467-72.
48. Andrew, S.E., Goldberg, Y.P., Kremer, B. et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993, 4: 398-403.
49. Brinkman, R.R., Mezei, M.M., Theilmann, J. et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997, 60: 1202-10.
50. Snell, R.G., MacMillan, J.C., Cheadle, J.P. et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 1993, 4: 393-7.
51. Djousse, L., Knowlton, B., Hayden, M.R. et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics 2004, 5: 109-14.
52. Cummings, J.L. and Cole, G. Alzheimer disease. JAMA 2002, 287: 2335-8.
53. Selkoe, D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999, 399: A23-31.
54. Yankner, B.A. New clues to Alzheimer's disease: Unraveling the roles of amyloid and tau. Nat Med 1996, 2: 850-2.
55. De Vrij, F.M.S., Sluijs, J.A., Gregori, L. et al. Mutant ubiquitin expressed in Alzheimer's disease causes neuronal deathl. FASEB J 2001, 15: 2680-8.
56. Perry, G., Friedman, R., Shaw, G. et al. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A 1987, 84: 3033-6.
57. Arnold, S.E., Han, L.Y., Clark, C.M. et al. Quantitative neurohistological features of frontotemporal degeneration. Neurobiol Aging 2000, 21: 913-9.
58. Gong, B., Cao, Z., Zheng, P. et al. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006, 126: 775-88.
59. Dineley, K.T., Xia, X., Bui, D. et al. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem 2002, 277: 22768-80.
60. Tong, L., Thornton, P.L., Balazs, R. et al. Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem 2001, 276: 17301-6.
61. Vitolo, O.V., Sant'Angelo, A., Costanzo, V. et al. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A 2002, 99: 13217-21.
62. Gong, B., Vitolo, O. V., Trinchese, F. et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model following rolipram treatment. J Clin Invest 2004, 114: 1624-34.
63. Chain, D.G., Casadio, A., Schacher, S. et al. Mechanisms for generating the autonomous cAMP-dependent protein kinase required for long-term facilitation in Aplysia. Neuron 1999, 22: 147-56.
64. Lansbury, P.T. Jr. Improving synaptic function in a mouse model of AD. Cell 2006, 126: 655-7.
65. Sakurai, M., Ayukawa, K., Setsuie, R. et al. Ubiquitin C-terminal hydrolase L1 regulates the morphology of neural progenitor cells and modulates their differentiation. J Cell Sci 2006, 119: 162-71.
66. Harada, T., Harada, C., Wang, Y.-L. et al. Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury in vivo. Am J Pathol 2004, 164: 59-64.
67. McGowan, E., Eriksen, J. and Hutton, M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006, 22: 281-9.
68. Cookson, M.R. and Hardy, J. The persistence of memory. N Engl J Med 2006, 355: 2697-8.